- Home
- GGZ vs KZIA Comparison
GGZ vs KZIA Comparison
Compare GGZ & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GGZ | KZIA |
|---|---|---|
| Founded | N/A | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.0M | 154.5M |
| IPO Year | 2013 | 2002 |
Fundamental Metrics
Financial Performance| Metric | GGZ | KZIA |
|---|---|---|
| Price | $16.42 | $13.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 6.1K | ★ 212.4K |
| Earning Date | 01-01-0001 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.35 | $4.86 |
| 52 Week High | $17.08 | $17.40 |
Technical Indicators
Market Signals| Indicator | GGZ | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 47.68 | 51.28 |
| Support Level | $16.36 | $11.39 |
| Resistance Level | $16.68 | $14.79 |
| Average True Range (ATR) | 0.22 | 1.22 |
| MACD | -0.05 | 0.07 |
| Stochastic Oscillator | 14.27 | 30.77 |
Price Performance
Historical ComparisonAbout GGZ Gabelli Global Small and Mid Cap Value Trust (The) of Beneficial Interest
The Gabelli Global Small and Mid Cap Value Trust is a diversified closed-ended management investment company whose investment objective is long-term capital growth. It invests in equity securities such as common stock and preferred stock of companies.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.